AWI vs KEX

AWI's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite strong profitability metrics like a 38.03% ROE and solid earnings growth, elevated valuation multiples and weak insider sentiment weigh on the outlook. The stock trades above its Graham Number of $56.59 and near its intrinsic value estimate of $184.15, suggesting limited margin of safety. Analysts maintain a 'buy' recommendation with a $211.10 target, implying upside, but recent insider selling and deteriorating short-term earnings momentum raise caution.

KEX exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.34. While the stock trades at a significant premium to its Graham Number ($94.55), it remains below its growth-based Intrinsic Value ($186.44), reflecting a market that is pricing in explosive recent earnings growth (128% YoY). The company's consistent track record of EPS beats over 25 quarters provides high confidence in management's execution, although heavy insider selling by the CEO and CFO serves as a cautionary signal.